11:04 AM EDT, 05/14/2024 (MT Newswires) -- Centogene ( CNTG ) said Tuesday that the company and partner Evotec (EVO) discovered a new small molecule that has the potential to treat patients with type-2 and type-3 Gaucher disease, or neuronopathic Gaucher disease.

The companies have extended their collaboration for another year, granting Evotec a research and development license for the continued development activities, Centogene ( CNTG ) said.

Evotec now has an exclusive option through March 31, 2025, to decide whether to sign a license agreement acquiring Centogene's ( CNTG ) share of the intellectual property generated throughout the companies' collaboration.

Centogene ( CNTG ) would receive an up-front fee, milestone payments, as well as additional royalties in exchange for a global exclusive license, it said.

Centogene ( CNTG ) shares were up 1.6% in recent trading, while Evotec rose 2.1%.

Price: 0.40, Change: +0.01, Percent Change: +1.61